299 related articles for article (PubMed ID: 33741908)
1. CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer.
Ahmed M; Soares F; Xia JH; Yang Y; Li J; Guo H; Su P; Tian Y; Lee HJ; Wang M; Akhtar N; Houlahan KE; Bosch A; Zhou S; Mazrooei P; Hua JT; Chen S; Petricca J; Zeng Y; Davies A; Fraser M; Quigley DA; Feng FY; Boutros PC; Lupien M; Zoubeidi A; Wang L; Walsh MJ; Wang T; Ren S; Wei GH; He HH
Nat Commun; 2021 Mar; 12(1):1781. PubMed ID: 33741908
[TBL] [Abstract][Full Text] [Related]
2. Combined CRISPRi and proteomics screening reveal a cohesin-CTCF-bound allele contributing to increased expression of RUVBL1 and prostate cancer progression.
Tian Y; Dong D; Wang Z; Wu L; Park JY; ; Wei GH; Wang L
Am J Hum Genet; 2023 Aug; 110(8):1289-1303. PubMed ID: 37541187
[TBL] [Abstract][Full Text] [Related]
3. Validation of prostate cancer risk variants rs10993994 and rs7098889 by CRISPR/Cas9 mediated genome editing.
Wang X; Hayes JE; Xu X; Gao X; Mehta D; Lilja HG; Klein RJ
Gene; 2021 Feb; 768():145265. PubMed ID: 33122083
[TBL] [Abstract][Full Text] [Related]
4. Deciphering essential cistromes using genome-wide CRISPR screens.
Fei T; Li W; Peng J; Xiao T; Chen CH; Wu A; Huang J; Zang C; Liu XS; Brown M
Proc Natl Acad Sci U S A; 2019 Dec; 116(50):25186-25195. PubMed ID: 31727847
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation and cis-regulation of gene expression by prostate cancer risk SNPs.
Dai JY; Wang X; Wang B; Sun W; Jordahl KM; Kolb S; Nyame YA; Wright JL; Ostrander EA; Feng Z; Stanford JL
PLoS Genet; 2020 Mar; 16(3):e1008667. PubMed ID: 32226005
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic insights into genetic susceptibility to prostate cancer.
Tian P; Zhong M; Wei GH
Cancer Lett; 2021 Dec; 522():155-163. PubMed ID: 34560228
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional Dysregulation of MYC Reveals Common Enhancer-Docking Mechanism.
Schuijers J; Manteiga JC; Weintraub AS; Day DS; Zamudio AV; Hnisz D; Lee TI; Young RA
Cell Rep; 2018 Apr; 23(2):349-360. PubMed ID: 29641996
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis.
Barros-Silva D; Costa-Pinheiro P; Duarte H; Sousa EJ; Evangelista AF; Graça I; Carneiro I; Martins AT; Oliveira J; Carvalho AL; Marques MM; Henrique R; Jerónimo C
Cell Death Dis; 2018 Feb; 9(2):167. PubMed ID: 29415999
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer risk SNP rs10993994 is a trans-eQTL for SNHG11 mediated through MSMB.
Bicak M; Wang X; Gao X; Xu X; Väänänen RM; Taimen P; Lilja H; Pettersson K; Klein RJ
Hum Mol Genet; 2020 Jun; 29(10):1581-1591. PubMed ID: 32065238
[TBL] [Abstract][Full Text] [Related]
10. Dissecting transcription of the 8q24-MYC locus in prostate cancer recognizes the equilibration between androgen receptor direct and indirect dual-functions.
Guo J; Wei Z; Jia T; Wang L; Nama N; Liang J; Liao X; Liu X; Gao Y; Liu X; Wang K; Fu B; Chen SS
J Transl Med; 2023 Oct; 21(1):716. PubMed ID: 37828515
[TBL] [Abstract][Full Text] [Related]
11. An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer.
Wasserman NF; Aneas I; Nobrega MA
Genome Res; 2010 Sep; 20(9):1191-7. PubMed ID: 20627891
[TBL] [Abstract][Full Text] [Related]
12. CRISPR-mediated deletion of prostate cancer risk-associated CTCF loop anchors identifies repressive chromatin loops.
Guo Y; Perez AA; Hazelett DJ; Coetzee GA; Rhie SK; Farnham PJ
Genome Biol; 2018 Oct; 19(1):160. PubMed ID: 30296942
[TBL] [Abstract][Full Text] [Related]
13. Epigenome editing strategies for the functional annotation of CTCF insulators.
Tarjan DR; Flavahan WA; Bernstein BE
Nat Commun; 2019 Sep; 10(1):4258. PubMed ID: 31534142
[TBL] [Abstract][Full Text] [Related]
14. Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element.
Cho SW; Xu J; Sun R; Mumbach MR; Carter AC; Chen YG; Yost KE; Kim J; He J; Nevins SA; Chin SF; Caldas C; Liu SJ; Horlbeck MA; Lim DA; Weissman JS; Curtis C; Chang HY
Cell; 2018 May; 173(6):1398-1412.e22. PubMed ID: 29731168
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9 offers a new tool for studying the role of chromatin architecture in disease pathogenesis.
Guo X; Dean A
Genome Biol; 2018 Nov; 19(1):185. PubMed ID: 30400943
[TBL] [Abstract][Full Text] [Related]
16. MYC reshapes CTCF-mediated chromatin architecture in prostate cancer.
Wei Z; Wang S; Xu Y; Wang W; Soares F; Ahmed M; Su P; Wang T; Orouji E; Xu X; Zeng Y; Chen S; Liu X; Jia T; Liu Z; Du L; Wang Y; Chen S; Wang C; He HH; Guo H
Nat Commun; 2023 Mar; 14(1):1787. PubMed ID: 36997534
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of regulatory SNPs that modulate transcription factor chromatin binding and gene expression in prostate cancer.
Jin HJ; Jung S; DebRoy AR; Davuluri RV
Oncotarget; 2016 Aug; 7(34):54616-54626. PubMed ID: 27409348
[TBL] [Abstract][Full Text] [Related]
18. A functional variant at a prostate cancer predisposition locus at 8q24 is associated with PVT1 expression.
Meyer KB; Maia AT; O'Reilly M; Ghoussaini M; Prathalingam R; Porter-Gill P; Ambs S; Prokunina-Olsson L; Carroll J; Ponder BA
PLoS Genet; 2011 Jul; 7(7):e1002165. PubMed ID: 21814516
[TBL] [Abstract][Full Text] [Related]
19. Interactions of
Lin HY; Callan CY; Fang Z; Tung HY; Park JY
Cancer Epidemiol Biomarkers Prev; 2019 Jun; 28(6):1067-1075. PubMed ID: 30914434
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation modulated genetic variant effect on gene transcriptional regulation.
Zeng Y; Jain R; Lam M; Ahmed M; Guo H; Xu W; Zhong Y; Wei GH; Xu W; He HH
Genome Biol; 2023 Dec; 24(1):285. PubMed ID: 38066556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
